Mirimus

Mirimus is a private, preclinical-stage biotech founded in 2010 with a hybrid business model combining contract research services with internal therapeutic and diagnostic platform development. The company leverages deep expertise in RNA interference (RNAi), CRISPR, and genetic engineering to build advanced preclinical models and develop novel approaches in molecular diagnostics and therapeutics. Its scientific foundation is exceptional, being co-founded and advised by world-renowned leaders in cancer biology, genetics, and genomics. While likely generating early revenue from its service arm, Mirimus's long-term value hinges on translating its platform technologies into proprietary clinical programs.

Integrated platform leveraging RNA interference (RNAi) and CRISPR-Cas genome editing for functional genomics, advanced animal/cell model generation, and development of nucleic acid-based therapeutics and diagnostics.

In preclinical services, Mirimus competes with large CROs (Charles River, Taconic) and specialized academic centers. In therapeutics/diagnostics, it faces competition from well-funded public and private biotechs focused on RNAi (Alnylam), CRISPR therapeutics (CRISPR Therapeutics, Intellia), and molecular diagnostics (Guardant Health, Exact Sciences). Its differentiation lies in its integrated model-building expertise and elite scientific roots.